Our technology enables the production of a complete autologous engineered tissue composed of extracellular matrix and cells derived from patients’ own tissues. The matrix is a thermo-responsive hydrogel, prepared by decellularization of patient’s omentum sample, while the cells are re-programmed from patient’s mature cells to form induced Pluripotent Stem Cells (iPSCs). Ex-vivo differentiation of iPSCs within the thermo-responsive hydrogel leads to the generation of a functional mature tissue.
Our proprietary technology platform is the foundation for engineering autologous neural implants. Differentiation of iPSCs within extra cellular matrix (ECM) creates functional neural tissue implants that can bridge and regenerate injured spinal cord.
In 2019, Matricelf licensed from Tel Aviv University the technology that enabled printing the first 3D human heart from human cells
Matricelf’s novel regenerative medicine platform aims to treat a range of medical conditions including Spinal Cord Injuries (SCI), Age-related Macular Degeneration (AMD), Parkinson’s Disease, Myocardial Infarction, etc.